# US 2014/0154205 A1 · Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154205 A1
- Document ID: US20140154205A1
- Status: Published application
- Kind: A1
- Application number: 14/176,257
- Filed: 2014-02-10
- Published: 2014-06-05
- Earliest claimed: 2007-08-16
- Assignees: Remedor Biomed Ltd.
- Applicants: Remedor Biomed Ltd.
- Inventors: Saher HAMED
- Web page: https://patentgrep.com/patent/US20140154205A1

## CPC

- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 39/04: Chelating agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

## Claims

### Claim 1

A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm2 tissue of Erythropoietin and about 100-300 μg per cm2 tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject.

### Claim 2

A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm2 tissue of Erythropoietin and about 100-300 μg per cm2 tissue of Fibronectin, thereby treating ischemia in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the connective tissue comprises collagen.

### Claim 4 (depends on 1)

The method of claim 1, wherein a dose of said Erythropoietin is about 20 μg per cm2 tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein a dose of said Fibronectin is about 200 μg per cm2 tissue.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid.

### Claim 7 (depends on 1)

The method of claim 1, wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly.

### Claim 8 (depends on 1)

The method of claim 1, wherein said Erythropoietin and said Fibronectin are in a co-formulation.

### Claim 9 (depends on 1)

The method of claim 1, wherein said Erythropoietin and said Fibronectin are in separate formulations.

### Claim 10 (depends on 2)

The method of claim 2, wherein a dose of said Erythropoietin is about 20 μg per cm2 tissue.

### Claim 11 (depends on 2)

The method of claim 2, wherein a dose of said Fibronectin is about 200 μg per cm2 tissue.

### Claim 12 (depends on 2)

The method of claim 2, further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid.

### Claim 13 (depends on 2)

The method of claim 2, wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly.

### Claim 14 (depends on 2)

The method of claim 2, wherein said Erythropoietin and said Fibronectin are in a co-formulation.

### Claim 15 (depends on 2)

The method of claim 2, wherein said Erythropoietin and said Fibronectin are in separate formulations.

### Claim 16 (depends on 1)

The method of claim 1, wherein the active ingredients administered to said subject consist of Erythropoietin and Fibronectin.

### Claim 17 (depends on 1)

The method of claim 1, wherein said administering is effected at least once a day.

### Claim 18

A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration.